Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure

J Cardiovasc Pharmacol. 2005 Oct;46(4):513-8. doi: 10.1097/01.fjc.0000177980.83810.2e.

Abstract

Short-term infusion of carperitide (atrial natriuretic peptide) has beneficial effects on neurohumoral factors; however, it remains unclear whether the effects are sustained for long-term infusion. To evaluate the effects of long-term infusion of carperitide on neurohumoral factors in patients with chronic congestive heart failure (CHF), we measured neurohumoral factors before and 1 hour after stopping carperitide infusion in 42 CHF patients. Carperitide infusion was continued for more than 2 days until there was symptomatic improvement of CHF. Patients were divided into 2 groups by the median value of infusion duration: group 1 (less than 7 days, n=21) and group 2 (more than 7 days, n=21). In group 1, aldosterone (ALD) and endothelin-1 (ET-1) were significantly increased after stopping carperitide. In contrast, ALD and ET-1 did not change after stopping carperitide in group 2. The molar ratio of cyclic guanosine monophosphate/atrial natriuretic peptide before stopping carperitide was significantly lower in group 2 than in group 1. Suppression of ALD and ET-1 was maintained for 7 days of carperitide infusion, but the beneficial effect on neurohumoral factors was attenuated after more than 7 days, probably through down-regulation of biologic receptors coupled with guanylate cyclase in CHF patients.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Aldosterone / metabolism*
  • Atrial Natriuretic Factor / administration & dosage
  • Atrial Natriuretic Factor / blood
  • Atrial Natriuretic Factor / therapeutic use*
  • Blood Pressure / drug effects
  • Cardiomyopathy, Dilated / blood
  • Cardiomyopathy, Dilated / drug therapy
  • Cardiomyopathy, Dilated / physiopathology
  • Chronic Disease
  • Cyclic GMP / blood
  • Endothelin-1 / metabolism*
  • Female
  • Heart Failure / blood
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Heart Rate / drug effects
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Myocardial Ischemia / blood
  • Myocardial Ischemia / drug therapy
  • Myocardial Ischemia / physiopathology
  • Natriuretic Peptide, Brain / blood
  • Stroke Volume / drug effects
  • Time Factors
  • Treatment Outcome

Substances

  • Endothelin-1
  • NPPA protein, human
  • Natriuretic Peptide, Brain
  • Aldosterone
  • Atrial Natriuretic Factor
  • Cyclic GMP